I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at rhart@forbes.com
Pfizer and BioNTech have begun a clinical trial for their omicron-specific coronavirus vaccine, the companies announced Tuesday, as vaccine makers scramble to reformulate shots to target the infectious variant. The study will evaluate the vaccine for safety, tolerability and strength of immune response in up to 1,420 healthy adults ages 18 to 55, the companies said in a statement.
The companies will test the vaccine in unvaccinated people as part of a three-shot course, as a booster shot in those who have received two Pfizer-BioNTech doses already and as a fourth dose for people who have already had three Pfizer-BioNTech shots.